Caption Management’s Regenxbio RGNX Stock Holding History

Caption Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,123	Closed	-$51.4K	–	1992
2025 Q3	$39.8K	Buy	+4,123	New	+$36.5K	﹤0.01%	1573
2024 Q1	–	Sell	-1,682	Closed	-$29.9K	–	1611
2023 Q4	$30.2K	Buy	+1,682	New	+$29.6K	﹤0.01%	1243
2023 Q2	–	Sell	-5,804	Closed	-$110K	–	1354
2023 Q1	$110K	Hold	5,804	–	–	﹤0.01%	965
2022 Q4	$132K	Buy	+5,804	New	+$131K	﹤0.01%	1109
2022 Q3	–	Sell	-8,700	Closed	-$258K	–	1792
2022 Q2	$215K	Buy	+8,700	New	+$217K	﹤0.01%	1223
2021 Q4	–	Sell	-5,000	Closed	-$170K	–	1884
2021 Q3	$210K	Buy	+5,000	New	+$180K	﹤0.01%	1338
2021 Q2	–	Sell	-16	Closed	-$572	–	1523
2021 Q1	$1K	Buy	+16	New	+$682	﹤0.01%	991
2020 Q4	–	Sell	-10,500	Closed	-$367K	–	1205
2020 Q3	$289K	Buy	+10,500	New	+$342K	0.01%	859

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's RGNX Position: Q4 2025 in Review

Caption Management sold out of Regenxbio (RGNX) in Q4 2025, closing a stake of 4,123 shares — an estimated $51.4K sold.

Caption Management first reported a position in RGNX in Q3 2020 and held it in 8 quarters. The position peaked at $289K in Q3 2020. 174 funds tracked by Wall St. Rank hold RGNX as of Q4 2025.

Caption Management reported no remaining Regenxbio position as of Q4 2025 after selling out during the quarter.
Caption Management sold 4,123 Regenxbio shares in Q4 2025, an estimated $51.4K.
Caption Management first reported a position in Regenxbio in Q3 2020 and held it in 8 quarters.
Caption Management's Regenxbio position peaked at $289K in Q3 2020.
174 funds tracked by Wall St. Rank held Regenxbio as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.